Status:
COMPLETED
TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema
Lead Sponsor:
Northern California Retina Vitreous Associates
Collaborating Sponsors:
Allergan
Conditions:
Macular Edema
Uveitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether an intravitreal dexamethasone implant (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.
Detailed Description
Uveitis accounts for more than 10% of all cases of severe vision loss in developed countries, which makes it possibly the fourth leading cause of blindness in the United States. Cystoid macular edema ...
Eligibility Criteria
Inclusion
- Uveitis CME with central subfoveal thickness \> 350 microns
- non-infectious uveitis
- Visual Acuity \> 20/32
Exclusion
- Visual Acuity worse than 20/200
- Moderate or severe glaucoma (as defined as \>2 topical ocular medications)
- Infectious uveitis
- Patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis, vaccinia, varicella, mycobacterial infections, and fungal diseases.
- Aphakic eyes with rupture of the posterior lens capsule
- Anterior Chamber intraocular Lens and rupture of the posterior lens capsule
- Hypersensitivity to any components of the Ozurdex
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01870440
Start Date
May 1 2013
End Date
February 1 2015
Last Update
March 11 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northern California Retina Vitreous Associates
Mountain View, California, United States, 94040